Show simple item record

dc.contributor.authorBelayev, Ludmila
dc.contributor.authorKhoutorova, Larissa
dc.contributor.authorAtkins, Kristal
dc.contributor.authorCherqui, Alice
dc.contributor.authorÁlvarez-Builla Gómez, Julio 
dc.contributor.authorBazan, Nicolas G.
dc.date.accessioned2009-04-29T11:07:12Z
dc.date.available2009-04-29T11:07:12Z
dc.date.issued2009
dc.identifier.bibliographicCitationBrain Research 1253 (2009) 184-190en
dc.identifier.issn0006-8993
dc.identifier.urihttp://hdl.handle.net/10017/2669
dc.description.abstractLAU-0901, a novel platelet-activating factor (PAF) receptor antagonist, is highly neuroprotective in a rodent model of cerebral ischemia. This study was conducted to establish whether the neuroprotection induced by LAU-0901 persists with chronic survival. Male Sprague–Dawley rats were anesthetized with isoflurane and subjected to 2 h of temporary middle cerebral artery occlusion (MCAo) induced by means of a poly-l-lisine-coated intraluminal nylon suture. Animals were treated with either LAU-0901 (60 mg/kg) or vehicle (45% cyclodextran) administered i.p. at 2 h from onset of MCAo. They received neurobehavioral examinations during MCAo (60 min) and then at 1, 2, 3, 7, 14, 21 and 28 days followed by histopathology at 30 days. LAU-0901 significantly improved the behavior compared to the vehicle group, beginning on day 1 (by 29%, p = 0.00007) and persisting throughout a 30-day survival period (42%, p = 0.0001). Compared with vehicle treatment, LAU-0901 treatment significantly increased volume of non-infarcted brain tissue loss relative to the unlesioned hemisphere (16.3 ± 4.6% vs. 46.0 ± 10.3%, respectively). These results establish that LAU-0901 confers enduring ischemic neuroprotection.en
dc.description.sponsorshipNIH Grant NS023002 (NGB)en
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherElsevieren
dc.rights© Elsevier, 2008en
dc.subjectLAU-0901en
dc.subjectPAF antagonisten
dc.subjectNeuroprotectionen
dc.subjectBehavioralen
dc.subjectHistopathologyen
dc.subjectMiddle cerebral artery occlusionen
dc.titleLAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the raten
dc.typeinfo:eu-repo/semantics/articleen
dc.subject.ecienciaBioquímicaes_ES
dc.subject.ecienciaBiochemistryen
dc.subject.ecienciaScienceen
dc.subject.ecienciaCienciaes_ES
dc.contributor.affiliationUniversidad de Alcalá. Departamento de Química Orgánica
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.brainres.2008.11.074
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.1016/j.brainres.2008.11.074
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen


Files in this item

Thumbnail

This item appears in the following Collection(s)